SLAMF1: A Protein Implicated in Many Diseases (G6504)

Target Name: SLAMF1

NCBI ID: G6504

SLAMF1

SLAMF1: A Protein Implicated in Many Diseases

SLAMF1 (Small Ligand-Affinity for MAb-conjugated Antibodies) is a protein that is expressed in many different tissues and cells in the body. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer. SLAMF1 has also been identified as a potential drug target and may be a biomarker for some diseases.

SLAMF1 is a member of the SLAM family of proteins, which are characterized by their ability to recognize and interact with small ligands, such as proteins or small molecules. The SLAMF1 protein is composed of 251 amino acids and has a calculated molecular mass of 31.1 kDa. It is expressed in many different tissues and cells, including the brain, muscle, heart, and blood cells.

SLAMF1 plays a key role in the immune response by regulating the movement of immune cells through the body. It is known to be involved in the development and maintenance of the blood-brain barrier, which is a barrier that separates the brain from the surrounding blood vessels and helps to protect the brain from harmful substances.

SLAMF1 is also involved in the regulation of inflammation and has been implicated in the development of a number of inflammatory diseases, including cancer. For example, studies have shown that high levels of SLAMF1 are associated with an increased risk of developing breast cancer.

In addition to its role in the immune response and inflammation, SLAMF1 is also a potential drug target. Its unique ability to recognize and interact with small ligands makes it a promising target for small molecule inhibitors. Several studies have shown that SLAMF1 is sensitive to inhibitors such as inhibitors of tyrosine kinase, a signaling pathway that is involved in many different diseases, including cancer.

Another potential use of SLAMF1 as a drug target is its role in the regulation of the blood-brain barrier. The blood-brain barrier is a complex process that helps to protect the brain from harmful substances, but it can also be a barrier to the delivery of drugs to the brain. By inhibiting the movement of immune cells through the blood-brain barrier, SLAMF1 may help to improve the delivery of drugs to the brain and improve the effectiveness of some treatments.

SLAMF1 is also a potential biomarker for some diseases. Its expression has been detected in a number of diseases, including cancer, and high levels of SLAMF1 have been associated with an increased risk of developing some of these diseases. For example, studies have shown that high levels of SLAMF1 are associated with an increased risk of developing lung cancer.

In conclusion, SLAMF1 is a protein that is involved in many different processes in the body. Its unique ability to recognize and interact with small ligands makes it a promising target for small molecule inhibitors, and its role in the immune response and blood-brain barrier makes it a potential drug target. Further research is needed to fully understand the role of SLAMF1 in these processes and to develop effective treatments.

Protein Name: Signaling Lymphocytic Activation Molecule Family Member 1

Functions: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. SLAMF1-induced signal-transduction events in T-lymphocytes are different from those in B-cells. Two modes of SLAMF1 signaling seem to exist: one depending on SH2D1A (and perhaps SH2D1B) and another in which protein-tyrosine phosphatase 2C (PTPN11)-dependent signal transduction operates. Initially it has been proposed that association with SH2D1A prevents binding to inhibitory effectors including INPP5D/SHIP1 and PTPN11/SHP-2 (PubMed:11806999). However, signaling is also regulated by SH2D1A which can simultaneously interact with and recruit FYN which subsequently phosphorylates and activates SLAMF1 (PubMed:12458214). Mediates IL-2-independent proliferation of activated T-cells during immune responses and induces IFN-gamma production (By similarity). Downstreaming signaling involves INPP5D, DOK1 and DOK2 leading to inhibited IFN-gamma production in T-cells, and PRKCQ, BCL10 and NFKB1 leading to increased T-cell activation and Th2 cytokine production (By similarity). Promotes T-cell receptor-induced IL-4 secretion by CD4(+) cells (By similarity). Inhibits antigen receptor-mediated production of IFN-gamma, but not IL-2, in CD4(-)/CD8(-) T-cells (By similarity). Required for IL-4 production by germinal centers T follicular helper (T(Fh))cells (By similarity). May inhibit CD40-induced signal transduction in monocyte-derived dendritic cells (PubMed:16317102). May play a role in allergic responses and may regulate allergen-induced Th2 cytokine and Th1 cytokine secretion (By similarity). In conjunction with SLAMF6 controls the transition between positive selection and the subsequent expansion and differentiation of the thymocytic natural killer T (NKT) cell lineage. Involved in the peripheral differentiation of indifferent natural killer T (iNKT) cells toward a regulatory NKT2 type (By similarity). In macrophages involved in down-regulation of IL-12, TNF-alpha and nitric oxide in response to lipopolysaccharide (LPS) (By similarity). In B-cells activates the ERK signaling pathway independently of SH2D1A but implicating both, SYK and INPP5D, and activates Akt signaling dependent on SYK and SH2D1A (By similarity). In B-cells also activates p38 MAPK and JNK1 and JNK2 (PubMed:20231852). In conjunction with CD84/SLAMF5 and SLAMF6 may be a negative regulator of the humoral immune response (By similarity). Involved in innate immune response against Gram-negative bacteria in macrophages; probably recognizes OmpC and/or OmpF on the bacterial surface, regulates phagosome maturation and recruitment of the PI3K complex II (PI3KC3-C2) leading to accumulation of PdtIns(3)P and NOX2 activity in the phagosomes (PubMed:20818396)

The "SLAMF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLAMF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets